Sunshine Biopharma: Adva-27a targeting multidrug resistant breast cancer cells

Sunshine公司抗癌药Ava-27a研究取得新进展 发布时间：2012-9-20 来源：药品资讯网信息中心Sunshine生物医药公司称其抗癌药Adva-27a研发进入新阶段,包括研发新药研究已经I期临床研究。 Sunshine生物医药公司总裁兼首席执行官Steve Slilaty说:"对于Adva-27a的研究我们已经取得了很大突破,接下来我们要筹集资金用于其临床研究和标准化生产。" 公司称Adva-27a能够有效治疗多种癌细胞。其中包括具有耐药性的乳腺癌细胞和小细胞肺癌细胞。 Ava-27a临床研究将首先用于治疗具有耐药性的乳腺癌细胞。 Sunshine已经筹集到46万美元用于Adva-27a生产及其I期临床研究。

Sunshine Biopharma has entered into a contract with Beta Pharma Canada to manufacture an initial batch of Adva-27a and provide synthesis parameters for future scale-up and large scale manufacturing of the drug. Adva-27a is an anti-cancer compound which has proven effective at killing multidrug resistant breast cancer cells (MCF-7/MDR) and small-cell lung cancer cells (H69AR). Sunshine president and CEO Steve Slilaty said the company is working with Beta Pharma Canada which has good in-house synthesis capability and can amass additional resources through its corporate affiliations. "We anticipate delivery of the new batch of Adva-27a together with the synthesis parameters by the end of the month," Slilaty added. Beta Pharma Canada, an affiliate of Beta Pharma, is a Canadian small-molecule drug discovery and manufacturing company specializing in design,